Spotlight Center on HIV Prevention Today


NIH's Dr. Dieffenbach Discusses Launch of HIV Vaccine Clinical Trial in South Africa

December 2, 2016

In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH's Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.

Read more about the HVTN 702 trial.

Related Stories

First New HIV Vaccine Efficacy Study in Seven Years Has Begun
HIV Vaccine: Where Are We?
First Trials of HIV Vaccine Using Broadly Neutralizing Antibodies Begin

This article was provided by

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.